This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Ankylosing Spondylitis Treatment Market

Market Insights on Ankylosing Spondylitis Treatment covering sales outlook, demand forecast & up-to-date key trends

Ankylosing Spondylitis Treatment Market By Route of Administration (Oral, Parenteral), Drug Class (Nonsteroidal Anti-inflammatory Drugs, Anti-Inflammatory Drugs, Immunosuppressive Drugs, TNF Blockers), Application (Adults, Juveniles) & Region - Forecast to 2020-2030

Ankylosing Spondylitis Treatment Market Outlook and Key Findings

  • The global ankylosing spondylitis treatment market is expected to grow at a steady CAGR through 2030
  • Ankylosing spondylitis treatment market players focusing on innovation & regulatory approvals
  • North America and Europe collectively account for more than 50% of market share – revenue concentrated in the US and EU4
  • Inclusion of nanocurcumin to bolster the ankylosing spondylitis treatment market in the forecast period

Ankylosing Spondylitis Treatment Market Analysis

As per Arthritis Care & Research,almost 20-50% of people suffering from ankylosing spondylitis are reported to show spinal progression of certain level in the last two years of follow-up.

The TNF inhibitor treatments and NSAIDs (Non-steroid anti-inflammatory drugs) have been cornerstone therapies regarding managing ankylosing spondylitis and other types of inflammatory arthritis conditions.

The European Congress of Rheumatology (EULAR) annual meeting presented a French study raising a concern that rheumatologists, in spite of being knowledgeable about biosimilars, abstain from switching over to them due to lack of confidence in this treatment option.

On the other hand, European Journal of Integrative Medicine, Sep 2019, stated that Moxibustion, a type of heat therapy combined with traditional treatments is likely to provide short-term benefit to the ones affected by ankylosing spondylitis. This therapy is already put into practice all over East Asia.

Besides, findings at the Universita Degli Studi del Molise (Italy) state that physiotherapy is advantageous for ankylosing spondylitis-affected patients.

Though anti-inteleukin medications and anti-tumor necrosis have improved prognosis for a sizable number of patients; physiotherapy helps those who do not respond positively to these drugs. Moreover, modern day treatments press for physical rehabilitation and therapy.

Of late, research conducted at the University of Medical Sciences (Iran) concluded that T reg cells (suppressing the immune system) were upregulated in ankylosing spondylitis-affected patients who received a dose of nanocurcumin for 4 months in a row. Turmeric contains curcumin in the form of a naturally-occurring yellow colored substance.

The factors mentioned above are expected to compel the governments to divert a greater portion of their revenue towards extensive research, thereby driving the ankylosing spondylitis treatment market.

Customize this Report

Let us know your requirement to get
100% FREE customization

Market Players are Focusing on R&D and Innovations

The ankylosing spondylitis treatment market players are focusing on innovation and approval to gain a competitive edge over one another.

This trend is bound to help the ankylosing spondylitis market stand in a better stead between 2020 and 2030.

For instance –

  • In Jun 2020, Germany-based real-world data stated that Simponi (golimumab), a TNF inhibitor, is one of the most effective therapies for ankylosing spondylitis-affected patients.
  • In Feb 2020, Taltz (ixekizumab) was approved by Health Canada for treating adults with ankylosing spondylitis who weren’t responsive to traditional therapies.
  • In Dec 2019, Avsola (infliximab-axxq), biosimilar to Remicade (infliximab) for treating ankylosing spondylitis, was approved by the US FDA. Amgen is the maker of this biosimilar.
  • In Nov 2019, AbbVie, at 2019 American College of Rheumatology (ACR)/Association for Rheumatology Professionals (ARP) Annual Meeting, presented positive results from phase 2  & 3 SELECT-AXIS 1 trial for treatment against ankylosing Spondylitis in the form of Rinvoq.
  • In Nov 2019, the US FDA approved Abrilada (adalimumab-afzb), biosimilar to Humira (adalimumab) for treating people infected with 7 inflammatory diseases (ankylosing spondylitis included). Abrilada is credited to Pfizer.
  • In Sep 2019, outcome of phase 2 study that examined filgotinib suggested that oral therapy could prove to be an effective treatment regarding active ankylosing spondylitis.

Covid-19 Impact on Ankylosing Spondylitis Market

Ankylosing Spondylitis infected patients need to be extra careful amidst Covid-19. If they, by any means, signal towards active respiratory infection, they should consult their medical practitioner before continuing with the medications as that infection could be Covid-19, which may ask for a combination of varied medications/precautions.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Ankylosing Spondylitis Treatment Market Trends

The healthcare industry is moving towards extensive research with regards to ankylosing spondylitis, so as to continue with the geometric progression on the count of innovations.

For instance –

  • In Jul 2020, scientists at Rockefeller University inferred that newly discovered “PRIME cells” are capable of tamping down the inflammation caused due to rheumatoid arthritis. As such, one could foretell and treat rheumatoid arthritis flares. This discovery is bound to open doors to invention of biosimilars to treat this kind of spondylitis before it reaches the advanced stage.
  • In Jun 2020, Celltrion Healthcare received recommendation from CHMP (Committee for Medicinal Products for Human Use) for use of Remsima in ankylosing spondylitis.
  • In Oct 2019, SAA (Spondylitis Association of America) entered into partnership with PatientPoint for improving education regarding spondylitis and also extend support to rheumatology practices all over the US.

Ankylosing Spondylitis Treatment Market: Regional Analysis

  • North America holds the largest share of ankylosing spondylitis treatment market due to feasible reimbursement scenario in the US coupled with massive approvals for biosimilars by the US FDA.
  • European ankylosing spondylitis treatment market is benefitting from governments investing in research regarding effective treatment for ankylosing spondylitis.
  • Asia Pacific is expected to witness a linear transition in the ankylosing spondylitis treatment market due to countries like India and China moving from indolence to awareness regarding ankylosing spondylitis treatment
Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Major Players in the Ankylosing Spondylitis Treatment Market

The ankylosing spondylitis treatment market players have been devising biosimilars to combat ankylosing spondylitis.

Also, branded drugs’ patent expiry is opening doors for biosimilars. For instance – Remicade expired in 2015. This resulted in Inflectra getting introduced in 2016. The year 2017 witnessed introduction of Renflexis. Likewise, in 2019, Avsola got introduced.

The major players in the ankylosing spondylitis treatment market include:

  • Wyeth
  • Mitsubishi Tanabe
  • Schering-Plough
  • Takeda
  • Amgen
  • Centocor
  • Abbott
  • Eisai
  • Pfizer

Ankylosing Spondylitis Treatment Market: The Way Forward

The ankylosing spondylitis treatment market, as stated by FMI, is expected to witness a steady growth rate between 2020 and 2030.

The market players are working on war footing to devise medications for ankylosing spondylitis.

Inorganic growth parameters could also be pondered about. For instance – strategic partnerships across various geographies could help in reaching out to more number of patients

Key Segment

Drug Class

  • Nonsteroidal Anti-inflammatory Drugs
  • Anti-Inflammatory Drugs
  • Immunosuppressive Drugs
  • TNF Blockers
  • JAK Inhibitors
  • Steroids
  • Biologics
  • Others

Route of Administration

  • Parenteral
  • Oral

Application

  • Adults
  • Juveniles

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa
Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Success Factors

    4.1. Product Adoption / Usage Analysis

    4.2. Product USPs / Features

    4.3. Key Promotional Strategies

5. Global Ankylosing spondylitis Treatment Market - Pricing Analysis

    5.1. Regional Pricing Analysis By Drug Class

    5.2. Pricing Break-up

        5.2.1. Manufacturer Level Pricing

        5.2.2. Distributor Level Pricing

    5.3. Global Average Pricing Analysis Benchmark

6. Global Ankylosing spondylitis Treatment Market Demand (in Value or Value in US$ Mn) Analysis 2015-2019and Forecast, 2020-2030

    6.1. Historical Market Value (US$ Mn) Analysis, 2015-2019

    6.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030

        6.2.1. Y-o-Y Growth Trend Analysis

        6.2.2. Absolute $ Opportunity Analysis

7. Market Background

    7.1. Macro-Economic Factors

        7.1.1. Global GDP Growth Outlook

        7.1.2. Increase In Spending per Capita Income

    7.2. Forecast Factors - Relevance & Impact

        7.2.1. Product Availability

        7.2.2. Rising Number of Ankylosing Spondylitis Cases

        7.2.3. Development of Ankylosing spondylitis Treatment Products

        7.2.4. Change in Lifestyle Pattern

    7.3. Value Chain Analysis

    7.4. Market Dynamics

        7.4.1. Drivers

        7.4.2. Restraints

        7.4.3. Opportunity Analysis

    7.5. COVID19 Crisis Analysis

        7.5.1. Current COVID19 Statistics and Probable Future Impact

        7.5.2. Current GDP Projection and Probable Impact

        7.5.3. Current Economic Projection as compared to 2008 Economic analysis

        7.5.4. COVID19 and Impact Analysis

            7.5.4.1. Revenue By Drug Class

            7.5.4.2. Revenue By Route of Administration

            7.5.4.3. Revenue By Application

            7.5.4.4. Revenue By Country

        7.5.5. 2020 Market Scenario

        7.5.6. Quarter by Quarter Forecast

        7.5.7. Projected recovery Quarter

        7.5.8. Recovery Scenario – Short term, Midterm and Long Term Impact

8. Global Ankylosing spondylitis Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Drug Class

    8.1. Introduction / Key Findings

    8.2. Historical Market Value (US$ Mn) Analysis By Drug Class, 2015 - 2019

    8.3. Current and Future Market Value (US$ Mn) Value Analysis and Forecast By Drug Class, 2020 - 2030

        8.3.1. Disease-Modifying Anitrheumatic Drugs (DMARDs)

        8.3.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

        8.3.3. Biologics

    8.4. Market Attractiveness Analysis By Drug Class  

9. Global Ankylosing spondylitis Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Route of Administration

    9.1. Introduction / Key Findings

    9.2. Historical Market Value (US$ Mn) Analysis By Route of Administration , 2015 - 2019

    9.3. Current and Future Market Value (US$ Mn) Value Analysis and Forecast By Route of Administration , 2020 - 2030

        9.3.1. Oral

        9.3.2. Parenteral

    9.4. Market Attractiveness Analysis By Route of Administration

10. Global Ankylosing spondylitis Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Application

    10.1. Introduction / Key Findings

    10.2. Historical Market Value (US$ Mn) Value Analysis By Application, 2015 - 2019

    10.3. Current and Future Market Value (US$ Mn) Value Analysis and Forecast By Application , 2020 - 2030

        10.3.1. Juveniles

        10.3.2. Adults

    10.4. Market Attractiveness Analysis By Application

11. Global Ankylosing spondylitis Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Region

    11.1. Introduction

    11.2. Historical Market Value (US$ Mn) Analysis By Region, 2015 - 2019

    11.3. Current Market Value (US$ Mn) Analysis and Forecast By Region, 2020 - 2030

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. Middle East and Africa (MEA)

        11.3.5. East Asia

        11.3.6. South Asia

        11.3.7. Oceania

    11.4. Market Attractiveness Analysis By Region

12. North America Ankylosing spondylitis Treatment Market Analysis 2015-2019 and Forecast 2020-2030

    12.1. Introduction

    12.2. Historical Market Value (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019

    12.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030

        12.3.1. By Country

            12.3.1.1. U.S.

            12.3.1.2. Canada

        12.3.2. By Drug Class

        12.3.3. By Route of Administration

        12.3.4. By Application

    12.4. Market Attractiveness Analysis

        12.4.1. By Drug Class

        12.4.2. By Route of Administration

        12.4.3. By Application

    12.5. Market Trends

    12.6. Key Market Participants - Intensity Mapping

    12.7. Drivers and Restraints - Impact Analysis

13. Latin America Ankylosing spondylitis Treatment Market Analysis 2015-2019 and Forecast 2020-2030

    13.1. Introduction

    13.2. Historical Market Value (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019

    13.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030

        13.3.1.  By Country

            13.3.1.1. Brazil

            13.3.1.2. Mexico

            13.3.1.3. Rest of Latin America

        13.3.2. By Drug Class

        13.3.3. By Route of Administration

        13.3.4. By Application

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Drug Class

        13.4.3. By Route of Administration

        13.4.4. By Application

    13.5. Market Trends

    13.6. Key Market Participants - Intensity Mapping

    13.7. Drivers and Restraints - Impact Analysis

14. Europe Ankylosing spondylitis Treatment Market Analysis 2015-2019 and Forecast 2020-2030

    14.1. Introduction

    14.2. Historical Market Value (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019

    14.3. Market Value (US$ Mn) By Market Taxonomy, 2020 - 2030

        14.3.1.  By Country

            14.3.1.1. Germany

            14.3.1.2. Italy

            14.3.1.3. France

            14.3.1.4. U.K.

            14.3.1.5. Spain

            14.3.1.6. BENELUX

            14.3.1.7. Russia

            14.3.1.8. Rest of Europe

        14.3.2. By Drug Class

        14.3.3. By Route of Administration

        14.3.4. By Application

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Drug Class

        14.4.3. By Route of Administration

        14.4.4. By Application

    14.5. Market Trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

15. South Asia Ankylosing spondylitis Treatment Market Analysis 2015-2019 and Forecast 2020-2030

    15.1. Introduction

    15.2. Historical Market Value (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019

    15.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030

        15.3.1.  By Country

            15.3.1.1. India

            15.3.1.2. Thailand

            15.3.1.3. Indonesia

            15.3.1.4. Malaysia

            15.3.1.5. Rest of South Asia

        15.3.2. By Drug Class

        15.3.3. By Route of Administration

        15.3.4. By Application

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug Class

        15.4.3. By Route of Administration

        15.4.4. By Application

    15.5. Market Trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

16. East Asia Ankylosing spondylitis Treatment Market Analysis 2015-2019 and Forecast 2020-2030

    16.1. Introduction

    16.2. Historical Market Value (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019

    16.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030

        16.3.1.  By Country

            16.3.1.1. China

            16.3.1.2. Japan

            16.3.1.3. South Korea

        16.3.2. By Drug Class

        16.3.3. By Route of Administration

        16.3.4. By Application

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Drug Class

        16.4.3. By Route of Administration

        16.4.4. By Application

    16.5. Market Trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

17. Oceania Ankylosing spondylitis Treatment Market Analysis 2015-2019 and Forecast 2020-2030

    17.1. Introduction

    17.2. Historical Market Value (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019

    17.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030

        17.3.1.  By Country

            17.3.1.1. Australia

            17.3.1.2. New Zealand

        17.3.2. By Drug Class

        17.3.3. By Route of Administration

        17.3.4. By Application

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Drug Class

        17.4.3. By Route of Administration

        17.4.4. By Application

    17.5. Market Trends

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

18. Middle East and Africa Ankylosing spondylitis Treatment Market Analysis 2015-2019 and Forecast 2020-2030

    18.1. Introduction

    18.2. Historical Market Value (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019

    18.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030

        18.3.1.  By Country

            18.3.1.1. GCC Countries

            18.3.1.2. Turkey

            18.3.1.3. Northern Africa

            18.3.1.4. South Africa

            18.3.1.5. Rest of Middle East and Africa

        18.3.2. By Drug Class

        18.3.3. By Route of Administration

        18.3.4. By Application

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Drug Class

        18.4.3. By Route of Administration

        18.4.4. By Application

    18.5. Market Trends

    18.6. Key Market Participants - Intensity Mapping

    18.7. Drivers and Restraints - Impact Analysis

19. Key and Emerging Countries Ankylosing spondylitis Treatment Market Analysis 2015-2019 and Forecast 2020-2030

    19.1. Introduction

        19.1.1. Market Value Proportion Analysis, By Key Countries

        19.1.2. Global Vs. Country Growth Comparison

    19.2. U.S. Ankylosing spondylitis Treatment Market Analysis

        19.2.1. By Drug Class

        19.2.2. By Route of Administration

        19.2.3. By Application

    19.3. Canada Ankylosing spondylitis Treatment Market Analysis

        19.3.1. By Drug Class

        19.3.2. By Route of Administration

        19.3.3. By Application

    19.4. Mexico Ankylosing spondylitis Treatment Market Analysis

        19.4.1. By Drug Class

        19.4.2. By Route of Administration

        19.4.3. By Application

    19.5. Brazil Ankylosing spondylitis Treatment Market Analysis

        19.5.1. By Drug Class

        19.5.2. By Route of Administration

        19.5.3. By Application

    19.6. U.K. Ankylosing spondylitis Treatment Market Analysis

        19.6.1. By Drug Class

        19.6.2. By Route of Administration

        19.6.3. By Application

    19.7. Germany Ankylosing spondylitis Treatment Market Analysis

        19.7.1. By Drug Class

        19.7.2. By Route of Administration

        19.7.3. By Application

    19.8. France Ankylosing spondylitis Treatment Market Analysis

        19.8.1. By Drug Class

        19.8.2. By Route of Administration

        19.8.3. By Application

    19.9. Italy Ankylosing spondylitis Treatment Market Analysis

        19.9.1. By Drug Class

        19.9.2. By Route of Administration

        19.9.3. By Application

    19.10. Spain Ankylosing spondylitis Treatment Market Analysis

        19.10.1. By Drug Class

        19.10.2. By Route of Administration

        19.10.3. By Application

    19.11. Russia Ankylosing spondylitis Treatment Market Analysis

        19.11.1. By Drug Class

        19.11.2. By Route of Administration

        19.11.3. By Application

    19.12. China Ankylosing spondylitis Treatment Market Analysis

        19.12.1. By Drug Class

        19.12.2. By Route of Administration

        19.12.3. By Application

    19.13. Japan Ankylosing spondylitis Treatment Market Analysis

        19.13.1. By Drug Class

        19.13.2. By Route of Administration

        19.13.3. By Application

    19.14. South Korea Ankylosing spondylitis Treatment Market Analysis

        19.14.1. By Drug Class

        19.14.2. By Route of Administration

        19.14.3. By Application

    19.15. India Ankylosing spondylitis Treatment Market Analysis

        19.15.1. By Drug Class

        19.15.2. By Route of Administration

        19.15.3. By Application

    19.16. Australia Ankylosing spondylitis Treatment Market Analysis

        19.16.1. By Drug Class

        19.16.2. By Route of Administration

        19.16.3. By Application

    19.17. New Zealand Ankylosing spondylitis Treatment Market Analysis

        19.17.1. By Drug Class

        19.17.2. By Route of Administration

        19.17.3. By Application

    19.18. GCC Countries Ankylosing spondylitis Treatment Market Analysis

        19.18.1. By Drug Class

        19.18.2. By Route of Administration

        19.18.3. By Application

    19.19. Turkey Ankylosing spondylitis Treatment Market Analysis

        19.19.1. By Drug Class

        19.19.2. By Route of Administration

        19.19.3. By Application

    19.20. South Africa Ankylosing spondylitis Treatment Market Analysis

        19.20.1. By Drug Class

        19.20.2. By Route of Administration

        19.20.3. By Application

20. Market Structure Analysis

    20.1. Market Analysis by Tier of Companies

    20.2. Market Concentration

    20.3. Market Share Analysis of Top Players

    20.4. Market Presence Analysis

        20.4.1. By Regional footprint of Players

        20.4.2. Product foot print by Players

        20.4.3. Channel Foot Print by Players

21. Competition Analysis

    21.1. Competition Dashboard

    21.2. Competition Benchmarking

    21.3. Competition Deep Dive

        21.3.1. AbbVie, Inc.

            21.3.1.1. Overview

            21.3.1.2. Product Portfolio

            21.3.1.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.1.4. Sales Footprint

            21.3.1.5. Strategy Overview

                21.3.1.5.1. Marketing Strategy

                21.3.1.5.2. Product Strategy

                21.3.1.5.3. Channel Strategy

        21.3.2. Amgen, Inc.

            21.3.2.1. Overview

            21.3.2.2. Product Portfolio

            21.3.2.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.2.4. Sales Footprint

            21.3.2.5. Strategy Overview

                21.3.2.5.1. Marketing Strategy

                21.3.2.5.2. Product Strategy

                21.3.2.5.3. Channel Strategy

        21.3.3. Pfizer, Inc.

            21.3.3.1. Overview

            21.3.3.2. Product Portfolio

            21.3.3.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.3.4. Sales Footprint

            21.3.3.5. Strategy Overview

                21.3.3.5.1. Marketing Strategy

                21.3.3.5.2. Product Strategy

                21.3.3.5.3. Channel Strategy

        21.3.4. Novartis AG

            21.3.4.1. Overview

            21.3.4.2. Product Portfolio

            21.3.4.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.4.4. Sales Footprint

            21.3.4.5. Strategy Overview

                21.3.4.5.1. Marketing Strategy

                21.3.4.5.2. Product Strategy

                21.3.4.5.3. Channel Strategy

        21.3.5. Eli Lilly and Company

            21.3.5.1. Overview

            21.3.5.2. Product Portfolio

            21.3.5.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.5.4. Sales Footprint

            21.3.5.5. Strategy Overview

                21.3.5.5.1. Marketing Strategy

                21.3.5.5.2. Product Strategy

                21.3.5.5.3. Channel Strategy

        21.3.6. UCB, Inc.

            21.3.6.1. Overview

            21.3.6.2. Product Portfolio

            21.3.6.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.6.4. Sales Footprint

            21.3.6.5. Strategy Overview

                21.3.6.5.1. Marketing Strategy

                21.3.6.5.2. Product Strategy

                21.3.6.5.3. Channel Strategy

        21.3.7. Johnson & Johnson Services, Inc.

            21.3.7.1. Overview

            21.3.7.2. Product Portfolio

            21.3.7.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.7.4. Sales Footprint

            21.3.7.5. Strategy Overview

                21.3.7.5.1. Marketing Strategy

                21.3.7.5.2. Product Strategy

                21.3.7.5.3. Channel Strategy

        21.3.8. Merck & Co., Inc.

            21.3.8.1. Overview

            21.3.8.2. Product Portfolio

            21.3.8.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.8.4. Sales Footprint

            21.3.8.5. Strategy Overview

                21.3.8.5.1. Marketing Strategy

                21.3.8.5.2. Product Strategy

                21.3.8.5.3. Channel Strategy

        21.3.9. Janssen Pharmaceuticals Inc

            21.3.9.1. Overview

            21.3.9.2. Product Portfolio

            21.3.9.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.9.4. Sales Footprint

            21.3.9.5. Strategy Overview

                21.3.9.5.1. Marketing Strategy

                21.3.9.5.2. Product Strategy

                21.3.9.5.3. Channel Strategy

        21.3.10. Sandoz International GmbH

            21.3.10.1. Overview

            21.3.10.2. Product Portfolio

            21.3.10.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.10.4. Sales Footprint

            21.3.10.5. Strategy Overview

                21.3.10.5.1. Marketing Strategy

                21.3.10.5.2. Product Strategy

                21.3.10.5.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, by Drug Class

Table 02: Global Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Route of Administration

Table 03: Global Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, by Application

Table 04: Global Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Region

Table 05: North America Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 06: North America Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

Table 7: North America Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 8: North America Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Application

Table 9: Latin America Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 10: Latin America Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

Table 11: Latin America Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 12: Latin America Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Application

Table 13: Europe Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 14: Europe Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

Table 15: Europe Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 16: Europe Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Application

Table 17: East Asia Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 18: East Asia Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

Table 19: East Asia Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 20: East Asia Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Application

Table 21: South Asia Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 22: South Asia Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

Table 23: South Asia Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 24: South Asia Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Application

Table 25: Oceania Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 26: Oceania Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

Table 27: Oceania Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 28: Oceania Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Application

Table 29: MEA Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 30: MEA Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

Table 31: MEA Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 32: MEA Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Application

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

Figure 01: Global Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis, 2015–2019

Figure 02: Global Ankylosing spondylitis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Analysis, 2020–2030

Figure 03: Global Ankylosing spondylitis Treatment Market Absolute $ Opportunity Analysis, 2020–2030

Figure 04: Global Ankylosing spondylitis Treatment Market Value Analysis by Drug Class –2020 & 2030

Figure 05: Global Ankylosing spondylitis Treatment Market Y-o-Y Growth Projections by Drug Class , 2020 – 2030

Figure 06: Global Ankylosing spondylitis Treatment Market Attractiveness Analysis By Drug Class, 2020-2030,

Figure 07: Global Ankylosing spondylitis Treatment Market Analysis by Route of Administration –2020 & 2030

Figure 08: Global Ankylosing spondylitis Treatment Market Y-o-Y Growth Projections by Route of Administration , 2020 – 2030

Figure 09: Global Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Route of Administration

Figure 10: Global Ankylosing spondylitis Treatment Market Analysis by Application –2020 & 2030

Figure 11: Global Ankylosing spondylitis Treatment Market Y-o-Y Growth Projections by Application , 2020 – 2030

Figure 12: Global Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, By Application

Figure 13: Global Ankylosing spondylitis Treatment Market Analysis by Region–2020 & 2030

Figure 14: Global Ankylosing spondylitis Treatment Market Y-o-Y Growth Projections by Region, 2020 – 2030

Figure 15: Global Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, By Region

Figure 16: North America Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis, 2015-2019

Figure 17: North America Ankylosing spondylitis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2020–2030

Figure 18: North America Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Country

Figure 19: North America Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Drug Class

Figure 20: North America Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, Route of Administration

Figure 21: North America Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Application

Figure 22: Latin America Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis, 2015-2019

Figure 23: Latin America Ankylosing spondylitis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2020–2030

Figure 24: Latin America Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Country

Figure 25: Latin America Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Drug Class

Figure 26: Latin America Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, Route of Administration

Figure 27: Latin America Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Application

Figure 28: Europe Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis, 2015-2019

Figure 29: Europe Ankylosing spondylitis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2020–2030

Figure 30: Europe Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Country

Figure 31: Europe Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Drug Class

Figure 32: Europe Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, Route of Administration

Figure 33: Europe Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Application

Figure 34: East Asia Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis, 2015-2019

Figure 35: East Asia Ankylosing spondylitis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2020–2030

Figure 36: East Asia Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Country

Figure 37: East Asia Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Drug Class

Figure 38: East Asia Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, Route of Administration

Figure 39: East Asia Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Application

Figure 40: South Asia Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis, 2015-2019

Figure 41: South Asia Ankylosing spondylitis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2020–2030

Figure 42: South Asia Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Country

Figure 43: South Asia Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Drug Class

Figure 44: South Asia Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, Route of Administration

Figure 45: South Asia Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Application

Figure 46: Oceania Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis, 2015-2019

Figure 47: Oceania Ankylosing spondylitis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2020–2030

Figure 48: Oceania Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Country

Figure 49: Oceania Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Drug Class

Figure 50: Oceania Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, Route of Administration

Figure 51: Oceania Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Application

Figure 52: MEA Ankylosing spondylitis Treatment Market Value (US$ Mn) Analysis, 2015-2019

Figure 53: MEA Ankylosing spondylitis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2020–2030

Figure 54: MEA Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Country

Figure 55: MEA Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Drug Class

Figure 56: MEA Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, Route of Administration

Figure 57: MEA Ankylosing spondylitis Treatment Market Attractiveness Analysis 2020-2030, by Application

Figure 58: U.S. Market Value Proportion Analysis

Figure 59: Global Vs. U.S. Growth Comparison

Figure 60: U.S. Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 61: U.S. Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 62: U.S. Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 63: Canada Market Value Proportion Analysis

Figure 64: Canada Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 65: Canada Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 66: Canada Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 67: Global Vs. Canada Growth Comparison

Figure 68: Brazil Market Value Proportion Analysis

Figure 69: Brazil Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 70: Brazil Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 71: Brazil Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 72: Global Vs. Brazil Growth Comparison

Figure 73: Mexico Market Value Proportion Analysis

Figure 74: Mexico Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 75: Mexico Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 76: Mexico Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 77: Global Vs. Mexico Growth Comparison

Figure 78: Argentina Market Value Proportion Analysis

Figure 79: Argentina Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 80: Argentina Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 81: Argentina Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 82: Global Vs. Argentina Growth Comparison

Figure 83: U.K. Market Value Proportion Analysis

Figure 84: U.K. Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 85: U.K. Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 86: U.K. Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 87: Global Vs. U.K. Growth Comparison

Figure 88: Germany Market Value Proportion Analysis

Figure 89: Germany Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 90: Germany Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 91: Germany Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 92: Global Vs. Germany Growth Comparison

Figure 93: France Market Value Proportion Analysis

Figure 94: France Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 95: France Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 96: France Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 97: Global Vs. France Growth Comparison

Figure 98: Italy Market Value Proportion Analysis

Figure 99: Italy Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 100: Italy Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 101: Italy Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 102: Global Vs. Italy Growth Comparison

Figure 103: Spain Market Value Proportion Analysis

Figure 104: Spain Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 105: Spain Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 106: Spain Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 107: Global Vs. Spain Growth Comparison

Figure 108: Russia Market Value Proportion Analysis

Figure 109: Russia Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 110: Russia Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 111: Russia Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 112: Global Vs. Russia Growth Comparison

Figure 113: China Market Value Proportion Analysis

Figure 114: China Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 115: China Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 116: China Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 117: Global Vs. China Growth Comparison

Figure 118: Japan Market Value Proportion Analysis

Figure 119: Japan Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 120: Japan Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 121: Japan Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 122: Global Vs. Japan Growth Comparison

Figure 123: South Korea Market Value Proportion Analysis

Figure 124: South Korea Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 125: South Korea Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 126: South Korea Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 127: Global Vs. South Korea Growth Comparison

Figure 128: India Market Value Proportion Analysis

Figure 129: India Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 130: India Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 131: India Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 132: Global Vs. India Growth Comparison

Figure 133: Indonesia Market Value Proportion Analysis

Figure 134: Indonesia Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 135: Indonesia Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 136: Indonesia Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 137: Global Vs. Indonesia Growth Comparison

Figure 138: Thailand Market Value Proportion Analysis

Figure 139: Thailand Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 140: Thailand Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 141: Thailand Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 142: Global Vs. Thailand Growth Comparison

Figure 143: Malaysia Market Value Proportion Analysis

Figure 144: Malaysia Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 145: Malaysia Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 146: Malaysia Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 147: Global Vs. Malaysia Growth Comparison

Figure 148: Australia Market Value Proportion Analysis

Figure 149: Australia Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 150: Australia Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 151: Australia Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 152: Global Vs. Australia Growth Comparison

Figure 153: New Zealand Market Value Proportion Analysis

Figure 154: New Zealand Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 155: New Zealand Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 156: New Zealand Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 157: Global Vs. New Zealand Growth Comparison

Figure 158: South Africa Market Value Proportion Analysis

Figure 159: South Africa Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 160: South Africa Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 161: South Africa Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 162: Global Vs. South Africa Growth Comparison

Figure 163: Turkey Market Value Proportion Analysis

Figure 164: Turkey Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 165: Turkey Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 166: Turkey Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 167: Global Vs. Turkey Growth Comparison

Figure 168: GCC Market Value Proportion Analysis

Figure 169: GCC Ankylosing spondylitis Treatment Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 170: GCC Ankylosing spondylitis Treatment Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 171: GCC Ankylosing spondylitis Treatment Market Share Analysis (%) By Application, 2020 & 2030

Figure 172: Global Vs. GCC Growth Comparison

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Ankylosing Spondylitis Treatment Market